PF-00489791 For The Treatment Of Raynaud's

Summary

The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.

Timeline

Start

2010-08-04

Primary completion

2011-05-31

Completion

2011-05-31

Outcome

Met primary endpoint

registry analysis (superiority or other test); PF-00489791 20 mg (PRP) vs Placebo (PRP); p = 0.0057; Adjusted Mean Difference -0.69 (80% CI -0.99 to -0.38); ANCOVA NCT01090492 ↗

Publications

• Su KY, Sharma M, Kim HJ, Kaganov E, Hughes I, Abdeen MH, Ng JHK. Vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev. 2021 May 17;5(5):CD006687. doi: 10.1002/14651858.CD006687.pub4.

Drugs

Indications